 |
|
|
| |
High Efficacy at Lower Doses of MK-5172 25 mg and 50 mg Daily for 12 Weeks in HCV Genotype (Gt)1 Treatment-Naive Noncirrhotic Patients
|
| |
| |
Reported by Jules Levin
AASLD Nov 1-5 Wash DC
AASLD: High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study - (11/05/13)
AASLD: Efficacy and Safety of an Interferon-Free Regimen of MK-5172 + Ribavirin for 12 Weeks or 24 Weeks in Treatment-Naive, Noncirrhotic Subjects With HCV GT1 Infection: The C-SPIRIT Study - (11/04/13)
AASLD: Merck at AASLD - (11/18/13)
64rd Annual Meeting of the American Association for the Study of Liver Diseases
Washington, DC Nov 1-5 2013
John M. Vierling,1 Martin Lagging,2 Ashley Brown,3 Ola Weiland,4 Parvez Mantry,5 Alnoor Ramji,6 Frank Weilert,7 Isaias Noel Gendrano III,8 Chris Gilbert,8 Boan Zhang,8 Peggy Hwang,8 Janice Wahl,8 Michael Robertson,8 Niloufar Mobashery8
1Baylor College of Medicine, Houston, TX, USA; 2Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; 3Imperial College Healthcare NHS Trust, London, UK; 4Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden; 5The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, USA; 6University of British Columbia, Vancouver, British Columbia, Canada; 7Waikato District Health Board, Hamilton, New Zealand; 8Merck & Co., Inc, Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
